Trials presi in esame
Seto T. et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013; 14(7): 590-598 [Apri]
Nokihara H. et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. J Clin Oncol 2016; 34 (abstr 9008) [Apri]
Gadgeel SM. et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer. J Clin Oncol 2016; 34: 4079-4085 [Apri]
Peters, et al. Randomised, multicentre, phase III, open-label study of alectinib vs crizotinib in treatment-naïve anaplastic lymphoma kinase (ALK)-positive advanced NSCLC (ALEX study). Annals of Oncology 2014; 25 (4): iv426-iv470 [Apri]
Approfondimenti generali
Neoplasie del polmone, Linee Guida AIOM, 2015. [Apri]
Novello S, et al. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines. Ann Oncol; 2016; 27 (suppl 5): v1-v27 [Apri]
Eberhardt WEE et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancerAnnals of Oncology 26: 1573–1588, 2015 [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Shaw AT, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016; 17: 234-242. [Apri]
Ou SH, et al. Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol 2016; 34: 661-668. [Apri]
Ohe Y. et al. A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP. J Clin Oncol 2015; 33 (abstr 8061) [Apri]